Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom

Summary

Skyhawk Therapeutics announced the expansion of its FALCON-HD pivotal trial for SKY-0515 in Huntington's Disease to the United States, Canada, and the United Kingdom, with over 175 patients enrolled across more than ten countries and twenty sites. The company reported that Phase 1/2 enrollment is complete and the drug has been generally well tolerated based on twelve months of patient data.